Page last updated: 2024-11-02

pd 98059 and MS (Multiple Sclerosis)

pd 98059 has been researched along with MS (Multiple Sclerosis) in 2 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Attia, SM2
Ahmad, SF2
Nadeem, A2
Attia, MSM1
Ansari, MA2
Alsaleh, NB1
Alasmari, AF2
Al-Hamamah, MA1
Alanazi, A1
Alshamrani, AA2
Bakheet, SA2
Harisa, GI1
Shahid, M1
Al-Mazroua, HA1
Alomar, HA1
AsSobeai, HM1

Other Studies

2 other studies available for pd 98059 and MS (Multiple Sclerosis)

ArticleYear
The small molecule Erk1/2 signaling pathway inhibitor PD98059 improves DNA repair in an experimental autoimmune encephalomyelitis SJL/J mouse model of multiple sclerosis.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2023, Volume: 889

    Topics: Animals; Antineoplastic Agents; DNA; DNA Repair; Encephalomyelitis, Autoimmune, Experimental; Mice;

2023
MAP kinase inhibitor PD98059 regulates Th1, Th9, Th17, and natural T regulatory cells in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
    European journal of pharmacology, 2023, Nov-15, Volume: 959

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental;

2023